Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Low quality of life and high HSS-29 scores increase risk of losing patients during treatment.

This study evaluated the Spanish version of the Hair Specific Skindex-29 questionnaire and found it sensitive to changes in health-related quality of life among women with female-pattern hair loss.

This study found that the Spanish version of the hair-specific Skindex-29 questionnaire effectively detected changes in health-related quality of life among women with female-pattern hair loss, and the scores were significantly correlated with the SF-12 survey results after treatment with a 5 alpha-reductase inhibitor.

This study found that the Spanish version of the Hair Specific Skindex 29 (HSS29) is a reliable and valid tool for assessing the quality of life impact of female androgenetic alopecia.

This study validated a Spanish version of the Hair Specific Skindex 29 scale for assessing quality of life in women with female androgenetic alopecia, showing similar psychometric properties to the original.

This study found that 49% of female breast cancer patients treated with CDK4/6 inhibitors for at least three months developed alopecia, which significantly impacted their quality of life, with greater alopecia severity leading to worse emotional and functional well-being.

PRO-C22 can help diagnose and monitor the severity of hidradenitis suppurativa.

This study developed a validated method to detect prohibited drugs in dietary supplements, finding minoxidil, triaminodil, and finasteride in some samples.

This review highlights that while pharmacotherapy, including biological agents, provides varying but often partial control of hidradenitis suppurativa depending on disease severity, significant challenges and high relapse rates persist, necessitating further research for more effective treatments.

This study reviewed the literature on low-dose oral minoxidil as a primary treatment for various hair loss disorders, concluding that it is a successful and well-tolerated alternative to topical minoxidil for patients with poor adherence to other therapies.

In this study on C57BL/6 mice, researchers found that cadmium chloride exposure led to metabolic disruption, accelerated skin aging, and impaired hair regeneration, with more severe effects observed at higher doses.

This paper reviews hidradenitis suppurativa, comparing its clinical and histopathological characteristics to acne, questioning the proposed link to terminal hair follicles, and reports no new results.

This study reports that a heparin-based sericin hydrogel encapsulating basic fibroblast growth factor significantly accelerated wound healing in mice by enhancing vascularization, re-epithelialization, and collagen deposition.

This review discusses the potential of low-dose oral minoxidil as a safe and effective treatment for certain hair disorders, including alopecia, but reports no new clinical results.

In this study, women with chronic telogen effluvium experienced reduced hair shedding after being treated with once daily oral minoxidil for 12 months, but facial hypertrichosis was a reported side effect, suggesting the need for further placebo-controlled research.

This review discusses the use of platelet-rich plasma for facial rejuvenation, acne scarring, and androgenic alopecia and reports positive outcomes but emphasizes the need for standardized preparation and application methods.

This study reported that a newly developed UHPLC-MS/MS method detected illegal synthetic hair-growth compounds in 10% of 76 hair-growth products, highlighting the need for ongoing monitoring to protect public health.

This study identified a new minoxidil analogue called triaminodil in an illegal hair-growth supplement, but no data on its chemical, toxicological, or pharmacological properties are available yet.

This study found that ECMs from papillary and dermal papilla fibroblasts support normal basement membrane formation, suggesting potential improvements for therapeutic biomaterials in skin engineering.

This commentary reviews clinical trials on platelet-rich plasma treatments for androgenetic alopecia and emphasizes the need for standardized preparation methods and concentrations; it reports no new clinical results.

This article describes the Frontiers journal series, highlighting its open-access approach and tiered publishing system, but it presents no new empirical findings.

This study reviewed literature on low-dose oral minoxidil as a treatment for hair loss, finding good compliance and tolerability, with mild adverse effects like hypertrichosis, which increase with higher doses.

This review outlines the major health consequences of anabolic-androgenic steroid abuse, with a focus on sexual and reproductive issues, and suggests management prioritizes cessation and relapse prevention due to lack of robust randomized trials.

This review discusses the processes of melanocyte stem cell quiescence and activation, focusing on their interaction with hair follicle stem cells, and highlights current research on hair graying mechanisms; it reports no new results.

This study developed a stable nanoemulsion-based hair serum containing M. oleifera seed oil, which maintained its physical characteristics and reduced the oil's sticky texture, making it more suitable for hair loss treatment compared to traditional formulations.

In this study, GV-350 treatment over three months improved iron status and reduced the impact of Telogen Effluvium on quality of life among 20 iron-deficient women, with no adverse events reported.

This review discusses the genetic factors involved in hair follicle morphogenesis and cycling and reports no new clinical results; it emphasizes the role of genes in hereditary hair diseases.

This study concluded that oral minoxidil is an effective and well-tolerated alternative to topical minoxidil for healthy patients struggling with application-related compliance issues.

This study concluded that a combined once-daily solution of 5% minoxidil and 0.01% tretinoin is as effective and safe as the conventional twice-daily 5% minoxidil application for treating androgenetic alopecia in men.

This study identified trilauric glyceride and decanoylcarnitine as potential biomarkers for diagnosing PCOS in patients with and without insulin resistance, suggesting significant metabolic alterations in these conditions.